CervoMed Raises $10 Million in Direct Offering
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
CervoMed ( (CRVO) ) just unveiled an update.
On June 22, 2026, CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million before fees and expenses. H.C. Wainwright & Co. acted as exclusive placement agent, and CervoMed plans to deploy the net proceeds for working capital and general corporate purposes, bolstering funding for its ongoing clinical programs in neurodegenerative diseases.
The financing follows recent clinical and regulatory milestones for neflamapimod, including a completed Phase 2b trial in dementia with Lewy bodies and alignment with the U.S. Food and Drug Administration on a potential registration pathway in November 2025. The additional capital supports CervoMed’s efforts to progress neflamapimod across multiple Phase 2 studies and positions the company to pursue further partnerships and funding needed to advance to Phase 3 in dementia with Lewy bodies.
The most recent analyst rating on (CRVO) stock is a Buy
with a $9.00 price target.
To see the full list of analyst forecasts on CervoMed stock,
see the CRVO Stock Forecast page.
Spark’s Take on CRVO Stock
According to Spark, TipRanks’ AI Analyst, CRVO is a Neutral.
The score is held back primarily by weak financial performance (minimal revenue, large losses, and ongoing cash burn), partially offset by favorable technical momentum and a set of positive corporate catalysts (financing runway extension, strengthened IP, and encouraging trial-related updates). Valuation remains constrained by unprofitability and the lack of a dividend yield figure.
To see Spark’s full report on CRVO stock,
click here.
More about CervoMed
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related brain disorders. Its lead oral small molecule candidate, neflamapimod, targets neuroinflammation and neurodegeneration and is being advanced in indications including dementia with Lewy bodies, nonfluent variant primary progressive aphasia and amyotrophic lateral sclerosis.
Average Trading Volume: 5,114,642
Technical Sentiment Signal: Sell
Current Market Cap: $39.26M
See more data about CRVO stock on TipRanks’ Stock Analysis page.
